UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549


                                    FORM 8-K
                                   -----------

                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

       Date of Report (Date of earliest event reported): April 2, 2015

                               CEL-SCI CORPORATION
                         ------------------------------
             (Exact name of registrant as specified in its charter)


     Colorado                          001-11889             84-0916344
-----------------------------     ---------------------  ---------------------
(State or other jurisdiction      (Commission File No.)    (IRS Employer
    of incorporation)                                      Identification No.)

                              8229 Boone Blvd. #802
                                Vienna, VA 22182
                         ------------------------------
          (Address of principal executive offices, including Zip Code)


      Registrant's telephone number, including area code: (703) 506-9460
                                                          --------------


                                       N/A
                   ------------------------------------------
          (Former name or former address if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligations of the registrant under any of the
following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act
    (17CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
    CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
    Exchange Act (17 CFR 240.14d-2(b)

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
    Exchange Act (17 CFR 240.13e-14c))



<PAGE>


Item 8.01   Other Events.

     The  following is an update  regarding the pending  arbitration  proceeding
CEL-SCI  Corporation v. inVentiv Health  Clinical,  LLC (f/k/a PharmaNet LLC and
PharmaNet GmbH (f/k/a PharmaNet AG):

     CEL-SCI initially retained inVentiv, a clinical research  organization,  to
conduct  the  Phase  III  Clinical  Trial  of  CEL-SCI's   investigational  drug
Multikine(C) (Leukocyte Interleukin,  Injection). CEL-SCI terminated inVentiv in
or about March 2013 and  replaced it with two clinical  research  organizations,
Aptiv Solutions,  Inc. and Ergomed Clinical Research Ltd. CEL-SCI's  arbitration
claim is  initiated  under  the  Commercial  Rules of the  American  Arbitration
Association,  pursuant  to the  parties'  contract,  and  alleges  (i) breach of
contract,  (ii) fraud in the  inducement,  and (iii)  common  law  fraud.  In an
amended statement of claim,  CEL-SCI has also alleged  professional  malpractice
against inVentiv. CEL-SCI seeks at least $50 million in damages.

     inVentiv,  which previously asserted (i) a breach of contract  counterclaim
against CEL-SCI,  seeking at least $2 million in damages for services  allegedly
performed by inVentiv, has alleged additional counterclaims against CEL-SCI, for
(ii) breach of  contract,  seeking at least $1 million in damages for  allegedly
using  inVentiv's name in connection  with  publications  and promotions,  which
inVentiv   claims  breached  a  provision  in  the  parties'   contract;   (iii)
opportunistic  breach,  restitution and unjust enrichment,  seeking at least $20
million in disgorgement of alleged unjust profits allegedly made by CEL-SCI as a
result  of the  purported  breaches  referenced  in  subsection  (ii);  and (iv)
defamation,  seeking at least $1 million in  damages  for  allegedly  defamatory
statements made about inVentiv.  CEL-SCI believes  inVentiv's  counterclaims are
meritless and intends to vigorously defend against them.

     As a result,  the  arbitration  hearing (the  arbitration  equivalent  of a
trial),  which was previously  scheduled for May 4, 2015,  has been  tentatively
rescheduled  for October 27, 2015 through  November 17, 2015. The arbitrator has
instructed the parties to hold this time period free on their calendars.

     Although  the  arbitrator  has allowed  both  parties to  supplement  their
claims,   inVentiv  has  moved  to  dismiss   CEL-SCI's   additional  claim  for
professional malpractice, which CEL-SCI will vigorously oppose.



                                       2
<PAGE>


                                   SIGNATURES

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


Date:  April 2, 2015
                                 CEL-SCI CORPORATION



                                 By:  /s/ Patricia B. Prichep
                                      ----------------------------------------
                                      Patricia B. Prichep
                                         Senior Vice President of Operations





                                       3
[{"type": "8-K", "sequence": "1", "filename": "form8kitem801inventiv4-15.txt", "description": "8-KRE INVENTIV ARBITRATION", "secsgml_size_bytes": 5296}]
{"company-data": {"conformed-name": "CEL SCI CORP", "cik": "0000725363", "assigned-sic": "2836", "irs-number": "840916344", "state-of-incorporation": "CO", "fiscal-year-end": "0930"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-11889", "film-number": "15748236"}, "business-address": {"street1": "8229 BOONE BLVD .", "street2": "SUITE 802", "city": "VIENNA", "state": "VA", "zip": "22182", "phone": "7035069460"}, "mail-address": {"street1": "8229 BOONE BLVD.", "street2": "SUITE 802", "city": "VIENNA", "state": "VA", "zip": "22182"}, "former-company": {"former-conformed-name": "INTERLEUKIN 2 INC", "date-changed": "19880317"}}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549

                                    FORM 8-K
                                   -----------

                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

       Date of Report (Date of earliest event reported): April 2, 2015

                               CEL-SCI CORPORATION
                         ------------------------------
             (Exact name of registrant as specified in its charter)

     Colorado                          001-11889             84-0916344
-----------------------------     ---------------------  ---------------------
(State or other jurisdiction      (Commission File No.)    (IRS Employer
    of incorporation)                                      Identification No.)

                              8229 Boone Blvd. #802
                                Vienna, VA 22182
                         ------------------------------
          (Address of principal executive offices, including Zip Code)

      Registrant's telephone number, including area code: (703) 506-9460
                                                          --------------

                                       N/A
                   ------------------------------------------
          (Former name or former address if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligations of the registrant under any of the
following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act
    (17CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
    CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
    Exchange Act (17 CFR 240.14d-2(b)

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
    Exchange Act (17 CFR 240.13e-14c))
Item 8.01   Other Events.

     The  following is an update  regarding the pending  arbitration  proceeding
CEL-SCI  Corporation v. inVentiv Health  Clinical,  LLC (f/k/a PharmaNet LLC and
PharmaNet GmbH (f/k/a PharmaNet AG):

     CEL-SCI initially retained inVentiv, a clinical research  organization,  to
conduct  the  Phase  III  Clinical  Trial  of  CEL-SCI's   investigational  drug
Multikine(C) (Leukocyte Interleukin,  Injection). CEL-SCI terminated inVentiv in
or about March 2013 and  replaced it with two clinical  research  organizations,
Aptiv Solutions,  Inc. and Ergomed Clinical Research Ltd. CEL-SCI's  arbitration
claim is  initiated  under  the  Commercial  Rules of the  American  Arbitration
Association,  pursuant  to the  parties'  contract,  and  alleges  (i) breach of
contract,  (ii) fraud in the  inducement,  and (iii)  common  law  fraud.  In an
amended statement of claim,  CEL-SCI has also alleged  professional  malpractice
against inVentiv. CEL-SCI seeks at least $50 million in damages.

     inVentiv,  which previously asserted (i) a breach of contract  counterclaim
against CEL-SCI,  seeking at least $2 million in damages for services  allegedly
performed by inVentiv, has alleged additional counterclaims against CEL-SCI, for
(ii) breach of  contract,  seeking at least $1 million in damages for  allegedly
using  inVentiv's name in connection  with  publications  and promotions,  which
inVentiv   claims  breached  a  provision  in  the  parties'   contract;   (iii)
opportunistic  breach,  restitution and unjust enrichment,  seeking at least $20
million in disgorgement of alleged unjust profits allegedly made by CEL-SCI as a
result  of the  purported  breaches  referenced  in  subsection  (ii);  and (iv)
defamation,  seeking at least $1 million in  damages  for  allegedly  defamatory
statements made about inVentiv.  CEL-SCI believes  inVentiv's  counterclaims are
meritless and intends to vigorously defend against them.

     As a result,  the  arbitration  hearing (the  arbitration  equivalent  of a
trial),  which was previously  scheduled for May 4, 2015,  has been  tentatively
rescheduled  for October 27, 2015 through  November 17, 2015. The arbitrator has
instructed the parties to hold this time period free on their calendars.

     Although  the  arbitrator  has allowed  both  parties to  supplement  their
claims,   inVentiv  has  moved  to  dismiss   CEL-SCI's   additional  claim  for
professional malpractice, which CEL-SCI will vigorously oppose.

                                       2
SIGNATURES

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

Date:  April 2, 2015
                                 CEL-SCI CORPORATION

                                 By:  /s/ Patricia B. Prichep
                                      ----------------------------------------
                                      Patricia B. Prichep
                                         Senior Vice President of Operations

                                       3